Immutep Limited

NasdaqGM:IMMP 株式レポート

時価総額：US$59.2m

Immutep 配当と自社株買い

配当金 基準チェック /06

Immutep配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-60.7%

バイバック利回り

総株主利回り-60.7%
将来の配当利回り0%
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

Seeking Alpha • May 08

Immutep Limited: Surging On Positive Head And Neck Data

Summary Immutep's eftilagimod shows promising results in head and neck cancer, with a median overall survival of 17.6 months, significantly higher than what has been observed with other approaches. IMMP is well-capitalized with $146.3 million in liquidity, ensuring operations can continue without imminent dilution and funding issues. Despite promising phase 2 data, the fate of eftilagimod remains uncertain, with future trials and FDA discussions critical for potential accelerated approval. The positive TACTI-003 readout strengthens my "Buy" sentiment, though risks remain in this challenging cancer treatment landscape. Read the full article on Seeking Alpha
Seeking Alpha • Jan 28

Immutep Limited: Continuing To Make The Case For Eftilagimod

Summary Immutep Limited remains a “Buy” due to promising pipeline updates and strong financials, despite inherent high-risk/high-reward dynamics. Key trials for eftilagimod show encouraging results, particularly in non-small cell lung cancer and soft tissue sarcoma, enhancing the drug's potential. Financially, IMMP has a cash runway at least to 2026, supporting ongoing and future clinical trials without immediate funding concerns. Recent clinical data suggest meaningful advancements in LAG-3 therapeutics, reinforcing the investment thesis and highlighting IMMP's undervalued status. Read the full article on Seeking Alpha
Seeking Alpha • Nov 15

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Summary Positive results from phase 1 INSIGHT-003 study, using eftilagimod alpha in combination with KEYTRUDA and chemotherapy in treating first-line metastatic non-squamous NSCLC patients. Additional data from the phase 1 INSIGHT-003 study is expected in 2025, with plans to initiate a phase 3 TACTI-004 study targeting the same patient population. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031. Results from the phase 2b TACTI-003 study, using efti + KEYTRUDA to treat 1st-line recurrent/metastatic head and neck squamous cell carcinoma, expected in 2025; OS set as primary endpoint. Read the full article on Seeking Alpha
Seeking Alpha • Jul 15

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Summary Immutep Limited achieved positive results in the phase 2b study, using efti + Keytruda for the treatment of patients with 1st-line head and neck squamous cell carcinoma; Both PD-L1 positive and negative patients. Company to meet with FDA to be in a position to initiate a phase 3 study using efti + Keytruda for the treatment of patients with 1st-line HNSCC. Merck supply collaboration agreement in place to advance phase 3 study, using efti + Keytruda + chemotherapy for the treatment of 1stline NSCLC patients. Keytruda had become one of the top-selling drugs in 2023, with sales exceeding $25 billion; Efti has shown to help double several efficacy measures when added to Keytruda. Read the full article on Seeking Alpha
Seeking Alpha • May 01

Immutep: Realizing The Expected Catalysts, With More To Come

Summary Immutep Limited is focused on developing novel treatments targeting LAG3, an immune checkpoint, for various tumor types. The company's pipeline includes eftilagimod, which has shown promising response rates in thoracic malignancies. Immutep should have sufficient funding for 9–10 quarters of research and has demonstrated promising early signals of efficacy and safety. Read the full article on Seeking Alpha
Seeking Alpha • Oct 04

Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype

The U.S. Food and Drug Administration (FDA) granted fast track designation to Immutep's (NASDAQ:IMMP) eftilagimod alpha (IMP321) in combination with Merck's (NYSE:MRK) Keytruda (pembrolizumab) to treat first line non-small cell lung cancer (NSCLC). The combo was granted the status for initial treatment of patients with stage 3B/4 NSCLC expressing PD-L1 Tumor Proportion Score ≥1%, not amenable to EGFR/ALK based therapy, due to data from a phase 2 trial called TACTI-002/KEYNOTE-798, the company said in an Oct. 4 press release. "Efti also offers a chemotherapy-free option for NSCLC patients in need of less toxic and more durable solutions," said Immutep CEO Marc Voigt. The efti/Keytruda combo had previously received the FDA's fast track status in April 2021 as a first-line treatment for recurrent or metastatic Head and Neck Squamous Cell Carcinoma. IMMP +7.21% to $1.71 premarket Oct. 4
Seeking Alpha • Sep 23

Immutep secures €1.8M cash in French government's research tax credit

Immutep (NASDAQ:IMMP) announced Friday it has received €1.8M cash from the French government in research and development tax incentive payment. The incentive comes under the government's research tax credit scheme under which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure. The biotech firm said it intends to use the proceeds to support the ongoing and planned global clinical development of eftilagimod alpha and the preclinical development of IMP761. Stock is up 5% in pre-market trading. Earlier: Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo
Seeking Alpha • Aug 30

Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo

Immutep (NASDAQ:IMMP) said the Japanese Patent Office granted a new patent for eftilagimod alpha in combination with a PD-1 pathway inhibitor. The patent titled, 'Combined Preparations for the Treatment of Cancer or Infection' protects intellectual property related to combined therapeutic preparations consisting of  immunotherapy candidate eftilagimod alpha and an anti-PD-(L)1 antibody, the company said in an Aug. 30 press release. The company added that the claims are also directed to related methods of use in treating cancer and infection. "This is especially meaningful when coupled with the very promising data we have reported from TACTI-002 in three cancer indications, along with the initiation of TACTI-003 in the past 12 months," said Immutep CEO Marc Voigt. The patent is expected to expire Jan. 8, 2036.
Seeking Alpha • Jul 06

Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761

Immutep (NASDAQ:IMMP) said it received a patent from the Japanese Patent Office related to its pre-clinical product candidate IMP761. The patent number number 7074341 titled 'Anti-LAG-3 Antibodies' is related to pharmaceutical compositions comprising IMP761 and the use of the compositions to treat T-cell mediated inflammatory and autoimmune diseases, according to the company's July 6 press release. The patent will expiry on Sept. 1, 2036.
Seeking Alpha • Jun 12

Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player

Immutep has been developing anti-LAG3 compounds for over a decade. Recent approval of the first such compound from BMY was a watershed event. However, IMMP has a long way to go.
Seeking Alpha • Mar 21

Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play

FDA approval of Bristol Myers Opdualag/relatlimab anti-LAG3 carries positive implications for LAG3 pure-play Immutep’s entire pipeline. From an anti-LAG3 perspective, the FDA approval is directly positive for Immutep's recently unveiled oral, small molecule anti-LAG3 program and its out-licensed anti-LAG3 program to Novartis. Like anti-PD1 (Keytruda, Opvido) & anti-CLTA4 (Yervoy), LAG3 may be a key checkpoint in oncology. Yet, unlike PD1/CTLA4, LAG3 is unique in that both its activation & inhibition kills cancer. This relatively unknown pure-play on the emerging checkpoint LAG3 (Lymphocyte Activating Gene-3) has collaborations with Novartis, Merck, Pfizer, Merck KGaA, GlaxoSmithKline, EOC Pharma, Labcorp, etc. As its clinical data continues to strengthen, like it consistently has over the past few years, Immutep is seemingly well situated for strategic deals or its potential acquisition.
Seeking Alpha • Jun 21

Immutep expands the evaluation of efti into a triple combination therapy, shares down 12%

Immutep (IMMP) has signed an agreement to commence a new Phase I trial, called INSIGHT-003, to evaluate the combination of lead product candidate eftilagimod alpha (“efti” or “IMP321”) in conjunction with an existing approved standard of care therapy consisting of a chemotherapy agent and an anti-PD-1 therapy. INSIGHT-003 will be run as an amendment to the protocol of the ongoing INSIGHT trial as the third arm (Stratum C) with Prof. Dr. Salah-Eddin Al-Batran as lead investigator. Up to 20 patients

決済の安定と成長

配当データの取得

安定した配当: IMMPの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: IMMPの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Immutep 配当利回り対市場
IMMP 配当利回りは市場と比べてどうか？
セグメント配当利回り
会社 (IMMP)n/a
市場下位25% (US)1.4%
市場トップ25% (US)4.2%
業界平均 (Biotechs)2.4%
アナリスト予想 (IMMP) (最長3年)0%

注目すべき配当: IMMPは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: IMMPは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: IMMPの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: IMMPが配当金を報告していないため、配当金の持続可能性を計算できません。

高配当企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/26 03:22
終値2026/05/26 00:00
収益2025/12/31
年間収益2025/06/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Immutep Limited 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14

アナリスト機関
Melissa BensonBarrenjoey Markets Pty Limited
Thomas WakimBell Potter
Dylan DupuisB. Riley Securities, Inc.